Plain-English translation of NCT05382728 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether a new medication called works better than , a standard lung cancer treatment, for people with advanced non-small cell lung cancer that has a specific EGFR gene mutation. You would take one medication by mouth once daily while the other is a placebo (inactive pill), and neither you nor your doctors would know which is which at first. The study will measure how well the treatment works and what side effects occur.
is currently the standard first treatment for this type of lung cancer, but researchers believe this medication may work even better or have fewer side effects. This trial will help determine if the new treatment is a better option for patients.
You likely qualify if…
You likely don't qualify if…
You would take one tablet by mouth every day—either the new medication or a placebo, randomly assigned. You and your doctor would not know which you're receiving. You would attend regular clinic visits for check-ups, blood tests, and imaging scans to monitor how your cancer responds and watch for side effects. The study involves about 680 participants across multiple hospitals, and you would continue treatment as long as it is helping and you are tolerating it well.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
China
Phase
Large-scale testing
Sponsor
TYK Medicines, Inc
Enrollment target
~680 participants
Started
June 2022
Primary completion
May 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 80 Years
Last updated on clinicaltrials.gov in January 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Baohui Han, MD
Shanghai Chest Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.